Now accepting early access partners

Validation that moves
at the speed of science.

EVOLV | The Validation Factory

The first AI-native Computer System Validation platform built for GAMP 5, 21 CFR Part 11, and FDA QMSR. Generate compliant URS, automate risk assessment, and govern AI model changes — in minutes, not months.

Request Early Access ▶ Try Live Demo
GAMP 5 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 2025 GMP Annex 11 EU GMP

The Problem

CSV validation still runs on
spreadsheets and email chains.

Life sciences teams spend months on documentation that should take days. Regulatory guidance has changed. Most platforms haven't.

📋

Weeks to generate a URS

Requirements written manually in Word, reviewed in meetings, rewritten after audit findings. No regulatory traceability. No version control. Just documents.

⚠️

Regulations change. VMPs don't.

FDA's QMSR replaced the QSR on February 2, 2026. The PCCP final guidance landed August 2025. Most validation plans still cite rules that no longer exist.

🤖

AI in GxP with no governance

Drug interaction predictors and defect classifiers are being deployed with no PCCP, no change control, no audit trail. FDA inspectors are starting to notice.

The Platform

One platform.
The entire validation lifecycle.

From first requirement to post-market governance — every step compliant, auditable, and powered by AI that knows GAMP 5.

📄

Validation Factory

Generate GAMP 5-compliant URS from plain English. SMART refinement, PCCP verification, UR/FR decomposition, CSA test scripts, and PDF export with e-signature — in one guided workflow. What took days takes minutes.

URS Generation SMART Refinement UR/FR Decomposition CSA Test Scripts PDF + E-Signature
🔄

Change Control

ServiceNow change requests cross-referenced against your system portfolio in real time. GxP classification, GAMP-aware risk calculation using Severity × Occurrence × Detectability, and automatic revalidation flags. No spreadsheet required.

ServiceNow Integration GxP Classification GAMP Risk Matrix Revalidation Flags
🤖

AI Model Governance

Validated AI models treated as GAMP Category 5 assets. PCCP-aware change assessment aligned to FDA final guidance August 2025. Human-in-the-loop approval queue with 21 CFR Part 11 compliant audit trail.

PCCP Assessment HITL Governance FDA Aug 2025 21 CFR Part 11
📊

Portfolio Dashboard

Every system, every site, every phase — one view. RAG status, action items, regulatory due dates. Register new systems with GxP classification and track their full validation journey from plan to monitor. Built for QA Heads and CTOs.

RAG Status System Registry Lifecycle Tracking Multi-Site

See It In Action

Watch EVOLV handle in 4 minutes
what takes your team weeks.

Three real workflows. No voiceover scripts. No slides. Just the platform doing what it's built to do.

Demo 01

Portfolio Dashboard

Your entire validated system landscape — GAMP category, GxP status, risk level, revalidation due dates — in one view. Built for QA Heads and CTOs who need portfolio-wide compliance visibility instantly..

Demo 02

Change Control & GxP Classification

ServiceNow CR received → portfolio cross-reference → GAMP risk calculation → revalidation decision. Automatic.

Demo 03

AI Model Governance

AI model change in a validated system → PCCP assessment → Governance Hub → human-in-the-loop approval → 21 CFR Part 11 audit trail. Built for FDA's final guidance (Aug 2025).

Try the Validation Factory — live, right now.

Generate a real GAMP 5-compliant URS from your own requirement. No login required.

▶ Open Live Demo

Built For

EVOLV speaks the language
of regulated industries.

Whether you're defending a validation package in an inspection or governing 150 systems across 25 sites — EVOLV gives you the records to back it up.

🧪 QA Head · CSV Manager

Stop writing in Word. Start validating.

EVOLV generates, verifies, and manages your entire validation portfolio with a complete audit trail FDA inspectors can review on the spot.

  • URS from plain English in minutes
  • SMART requirements, auto-verified against GAMP 5
  • Full lifecycle tracking — Plan to Monitor
  • Audit-ready PDFs with e-signature

📋 VP Regulatory Affairs

FDA updated the rules. EVOLV already knows.

QMSR is mandatory. PCCP guidance is final. EVOLV cites the right regulations, routes the right changes, and produces the records you need when an inspector walks in.

  • Aligned to FDA PCCP Guidance Aug 18, 2025
  • 21 CFR Part 820 QMSR / ISO 13485:2016
  • SHA-256 tamper-evident audit trail
  • 21 CFR Part 11 electronic records

💻 CTO · CDO

Your AI models are GAMP Cat 5 assets.

EVOLV gives you the governance infrastructure to deploy AI in GxP contexts without regulatory exposure — with a full HITL approval layer and immutable decision records.

  • AI model registry with version history
  • PCCP-aware change assessment
  • Human-in-the-loop governance hub
  • Portfolio-wide RAG visibility

Regulatory Coverage

GAMP 5 (2nd Edition) 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 18, 2025 GMP Annex 11 EU GMP GLP ISO 17025 GDPR 21 CFR Part 820.35 QMSR FDA CSA Guidance 2022

Early Access

Join our first cohort of life sciences partners.

We're working with a small group of pharma and biotech companies before general availability. Early access partners get priority onboarding, direct access to the founding team, and founding-tier pricing locked in permanently.

🔒  We'll respond within 1 business day. Your information is never shared.

Quality Assurance Challenges in Life Sciences and How to Overcome Them

Mar 02, 2025

Understanding Quality Assurance in Life Sciences

Quality assurance (QA) is a critical component in the life sciences industry, ensuring that products are safe, effective, and meet regulatory standards. This process involves systematic checks and balances that help maintain the integrity of pharmaceutical, biotechnology, and medical device products. However, QA comes with its own set of challenges that can impact the efficiency and reliability of these products.

laboratory quality assurance

Challenge 1: Regulatory Compliance

One of the most significant challenges in QA for life sciences is adhering to stringent regulatory requirements. Regulatory bodies such as the FDA and EMA have detailed guidelines that must be followed, which can be complex and time-consuming. Companies must stay updated with these regulations to avoid compliance issues.

To overcome this challenge, organizations can implement robust compliance management systems that track regulatory changes and ensure that all processes align with current standards. Regular training sessions for staff can also help maintain a high level of compliance awareness.

Challenge 2: Data Integrity

Ensuring data integrity is another critical challenge. Inaccurate or incomplete data can lead to incorrect conclusions, affecting product quality and safety. Maintaining data integrity requires meticulous documentation and robust data management systems.

Employing advanced software solutions that provide real-time data monitoring and audit trails can help enhance data integrity. Additionally, fostering a culture of accountability among employees encourages meticulous record-keeping and adherence to data management protocols.

data management system

Challenge 3: Technological Integration

The rapid advancement of technology presents both opportunities and challenges in QA for life sciences. Integrating new technologies into existing systems can be difficult, particularly when legacy systems are involved. This can lead to disruptions in QA processes if not managed properly.

Organizations should adopt a strategic approach to technology integration by conducting thorough assessments of current systems and identifying areas for improvement. Collaborating with technology experts and investing in employee training can facilitate smoother transitions and optimize the benefits of new technological solutions.

Challenge 4: Resource Constraints

Resource constraints, including limited personnel and budgetary restrictions, often pose challenges to effective QA processes. With increasing demands for faster product releases, teams may find it difficult to maintain rigorous QA standards.

To address this issue, companies can leverage automation tools to streamline repetitive tasks, allowing QA teams to focus on more complex issues. Prioritizing resource allocation based on risk assessments can also ensure that critical areas receive the necessary attention and resources.

quality control team

Challenge 5: Risk Management

The dynamic nature of life sciences means that risk management is an ongoing challenge. Identifying potential risks early in the product development cycle is essential to mitigate potential issues.

Implementing a comprehensive risk management framework that includes regular risk assessments and contingency planning can help organizations proactively address potential threats. Engaging cross-functional teams in risk analysis also provides diverse perspectives that enhance risk identification and mitigation strategies.

Conclusion

Quality assurance in the life sciences industry is fraught with challenges, but by understanding these issues and implementing strategic solutions, organizations can maintain high standards of product quality and safety. Embracing technological advancements, fostering a culture of accountability, and prioritizing compliance are key steps toward overcoming these hurdles and ensuring successful QA outcomes.